PXN

Across TCGA pan-cancer cohorts, PXN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PXN data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PXN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PXN expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where PXN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.294	0.697	.002	31	view →
CCRCC	DFS	Median	All	0.592	0.899	<.001	19	view →
GBM	DFS	Quartile	All	0.551	0.790	.005	8	view →
LUAD	DFS	Quartile	III,IV	0.264	0.953	.006	3	view →
HNSC	DFS	Tertile	IV	0.778	0.537	.049	2	view →
LSCC	DFS	Median	II,III,IV	0.868	0.963	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PXN–PDAC (OS)

Open the PDAC breakdown →